[1] 郭宏华, 晁阳, 李岩,等. 抗病毒治疗对乙型肝炎相关原发性肝癌患者生活质量及预后的影响. 肝脏, 2012, 17:83-86.
[2] 杨培民, 徐洪燕. 奥沙利铂联合 TACE治疗原发性肝癌疗效分析. 肝脏, 2015:281-284.
[3] 张蓓. 雷替曲塞与卡培他滨联合奥沙利铂治疗老年晚期结直肠癌的疗效比较. 实用临床医药杂志, 2012, 16:99-101.
[4] Chen X. Clinical efficacy of oxaliplatin-based systemic chemotherapy in treating advanced hepatocellular carcinoma: a comparative study of two regimens. Journal of Clinical Hepatology, 2014, 30:1337-1340.
[5] Ling, Xu. Protective autophagy antagonizes oxaliplatin-induced apoptosis in gastric cancer cells. 癌症:英文版, 2011, 30:490-496.
[6] Satoh T, Bang Y J, Gotovkin E A, et al. Quality of Life in the Trastuzumab for Gastric Cancer Trial. Oncologist, 2014, 19:712-719.
[7] Clinical observation of Oxaliplatin combined with Gimeracil or Capecitabine in the treatment of advanced gastric cancer in elderly patients. China Medical Herald, 2012,23:61-63.
[8] 殷兆锋, 萧剑军, 彭杰文,等. 奥沙利铂联合卡培他滨治疗晚期原发性肝癌的临床观察. 临床医学工程, 2012, 19:740-742.
[9] 杨柳青, 秦叔逵, 华海清,等. XELOX方案治疗中晚期原发性肝癌的临床观察. 临床肿瘤学杂志, 2013, 18:704-708.
[10] Díazrubio E, Gómezespana A, Massutí B, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist, 2011, 17:15-25.
[11] 龚新雷, 秦叔逵, 王琳,等. 晚期肝细胞癌经XELOX方案系统化疗获临床治愈1例. 临床肿瘤学杂志, 2011, 16:480-480.
[12] 周江华, 魏蓉. XELOX方案和FOLFOX4方案治疗晚期胃癌的疗效和毒副作用的临床观察. 中外医学研究, 2012, 10:11-12.
[13] 王锋, 秦叔逵, 华海清,等. 含奥沙利铂化疗方案治疗对索拉非尼耐药的晚期原发性肝癌的临床观察. 临床肿瘤学杂志, 2014:226-230. |
